Ọgwụ Novonorm - ntuziaka na nyocha maka ndị ọrịa mamịrị

NovoNorm bụ ihe na-akpali akpali. Na mellitus na-arịa ọrịa shuga, a na-eji ọgwụ a eme ihe mgbe insulin ezughị n'ọbara onye ọrịa, a ghaghị imepụta ihe ndị na-emepụta ya. Otu njiri mara nke ọgwụ ahụ bụ nsonaazụ ya dị mkpirikpi na obere oge, nke na-enye gị ohere iji ya mezie ọkwa nke postprandial glycemia, ya bụ, belata glucose na nri.

Ọ bụrụ na -ejighị ya nke ọma, NovoNorm nwere ike bute hypoglycemia, yabụ, ọ dị ezigbo mkpa ịhọrọ usoro onunu ogwu zuru oke. Ọgwụ nke dọkịta, ka ọ ga-ede, ga-edepụta ọgwụ ahụ ka ọ nwere ike ịzụta ọgwụ. N’ọdịnihu, ndị na-arịa ọrịa shuga nwere ike ịgbanwe sọọsọ ya n’onwe ya, na-eji ntuzi aka ndị a maka ntuziaka maka ojiji

Ngwakọta na ụdị ntọhapụ

NovoNorm bụ onye nrụpụta NovoNordisk, bụ onye ama ama ama ama nke Denmark na-emepụta ọgwụ na ngwaahịa ndị metụtara ndị ọrịa shuga. A na-eme mbadamba na Germany na Denmark. Ihe dị n ’ọgwụ ahụ, ọgwụ akwụghachi, bụ ihe amino asịd ma ọ bụ n’usoro nzuzo. O sitere na German (onye na-emepụta Beringer Ingelheim).

Ọrịa shuga na oke nrụgide ga-abụ ihe mgbe ochie

• Normalization shuga -95%
• Mwepu nke akwara mbufụt - 70%
• Mwepu nke obi ike -90%
• Bibie ọbara mgbali elu - 92%
• Mmụba na ume n'ụbọchị, na-eme ka ụra na-ehi ụra n'abalị -97%

Otu mbadamba NovoNorm nwere ike ịnweta 0,5, 1 ma ọ bụ 2 mg nke ihe na-arụ ọrụ. Na mgbakwunye na ya, a na-etinye stachi, povidone, potassium polyacrylate, pluronic, glycerin, calcium hydrogen phosphate, na agba. Ha bụ ihe inyeaka, ya bụ, ha enweghị mmetụta ọgwụgwọ.

Otu esi ekpebi ọgwụ mbụ:

1. Iji chebe megide adịgboroja, akara mbadamba ọ bụla nwere akara nke NovoNordisk - ehi nsọ nke Ijipt oge ochie.
2. A na-etinye ọgwụ ahụ na foil blisters, nke ọ bụla nwere mbadamba iri na ise.
3. A na-eji bloda ahụ rụọ ọrụ nke ọma, nke na-enye gị ohere ikewapụ kwa ụbọchị otu na-enweghị ihe eji eme ihe
4. Agba nke mbadamba nkume nke dosages dị iche: 0,5 mg ọcha, 1 mg odo, 2 mg pinkish.

Ọnụahịa nke ngwugwu mejupụtara mbadamba 30 anaghị agafe 230 rubles. Enwere ike idobe ọgwụ ahụ maka afọ 5 na okpomọkụ nke 15-30 Celsius.

Principlekpụrụ nke ọrụ NovoNorma

Repaglinide bụ akụkụ nke otu ọgwụ na-akpọ meglitinides. Can nwere ike mata ha na njedebe nke glinid n'aha. Ha bụ usoro dị iche iche nke amino asịd, ọkachasị nke a na - enyeghachi - carbamoyl-methyl-benzoic. Ihe a na - enwe ike kegide mpaghara pụrụ iche nke ụzọ mmiri potassium dị na akpụkpọ ahụ nke mkpụrụ ndụ beta nke pancreatic. N'okpuru mmetụta nke repaglinide, a na-egbochi ọwa ndị a, nke na-eduga na ntinye nke calcium n'ime sel yana ịbawanye ụba insulin.

Ntọhapụ insulin nke NovoNorm na-amalite bụ nkeji 10 ka mbadamba ahụ banye na nri diges. Achọpụtara ọkwa kachasị n’ọbara n’agha nkeji iri ise. Ọ bụrụ na ị theụọ ọgwụ ahụ nkeji iri na ise tupu nri, uto nke glucose ọbara na njikọta insulin na-agbakọta oge, nke pụtara na glucose nwere ike ịhapụ arịa ndị ahụ ozugbo.

N'adịghị ka usoro sulfonylurea ndị a ma ama (Maninil, Amaril, Glibenclamide, wdg), ihe omume NovoNorm na-adabere na glycemia. Site na shuga nkịtị, ọ na-adị obere oge karịa inwe shuga dị elu. Mgbe etinyere Repaglinide, ọkwa insulin na-alaghachi n’ihu mgbe awa 3 gachara. Dị ka ndị dọkịta si kwuo, njirimara a na-ebelata ugboro ugboro na ogo nke hypoglycemia ma ọ bụrụ na ị doụbiga ya ókè. A na-atụle mkpali dị mkpirikpi nke ntọhapụ insulin dị ka ihe dị ntakịrị, na-egbochi mbelata nke mkpụrụ ndụ beta ngwa ngwa, ma na-esite n'ọrịa shuga.

Njirimara nke iwepu ahu

Repaglinide nwere ike ịbanye ngwa ngwa na nri diges, nke kpatara mbido nmalite ya. Bioavailability yana itinye uche n'ihe ikpeazụ n'ime ọbara ahụ dị iche (ihe ruru 60%) na ndị ọrịa mamịrị dị iche iche, yabụ, a ga-ahọpụta usoro ọgwụgwọ maka onye ọrịa ọ bụla n'otu n'otu.

Imeju na-eme ka mmiri ọgwụ ike Reaglinide rụpụta ya, ma otu elekere belata ọkara itinye uche ya na ọkara. Isi ihe dị na pharmacokinetics nke ihe bụ excretion site n'ahụ ahụ bụ isi site na nri diges. Dabere na ntuziaka ahụ, 92% nke repaglinide na-apụta site na feces, 2% n'ime ha n'ụdị ihe eji arụ ọrụ, 90% fọdụrụnụ n'ụdị metabolites. Akụrụ akụrụ ihe dịka 8%, nke na-enye ohere iji NovoNorm na ndị ọrịa mamịrị nwere ọrịa akụrụ siri ike. Ka elekere ise gachara, achọpụtaghị ịbugharị ọbara n'ime ọbara.

Onye ka edere ọgwụ ahu

Ndi NovoNorm ka edeputara maka ndi oria mamiri n’anu n’ahiri n’ahia:

1. Yana metformin ozugbo achọpụtara ọrịa ahụ, ọ bụrụ na ọbara ọgbụgba ahụ glycins dị elu karịa 9%, nke na-egosi nchọpụta ahụike mellitus nke ọrịa shuga ma ọ bụ n'ọrịa ya ngwa ngwa.
2. Dị ka onye nnọchi nke sulfonylureas, ọ bụrụ na ha na-contraindicated n'ihi ọrịa akụrụ, mmeghachi omume nfụkasị.
3. Dịka akụkụ nke usoro ọgwụgwọ siri ike, ndị ọrịa nwere ọrịa shuga ogologo oge, ma ọ bụrụ na ha nwere ụkọ insulin ma ọ bụ usoro 1 nke mmepụta ya na-agbagha (sugar na-ebili ngwa ngwa ma ọ daa daa ogologo oge mgbe ha risịrị nri).
4. Ndị ọrịa shuga na-enweghị ike ịhazi nri ha. A nwere ike gbanwee dose nke NovoNorm dabere na ụba nke carbohydrates na nri.

Ntụziaka maka iji ya na-adụ ọdụ na-ewere NovoNorm na metformin na glitazones. Dika ntuleta, ogwu a na agara ndi mmadu nke hypoglycemic aru, tinyere insulin. Nanị ihe dị iche bụ nkwadebe sulfonylurea. Nkwekọrịta ha na NovoNorm bụ nke a na-anabata, mana anaghị atụ aro ya, ebe ọ nwere ike ibute hypoglycemia dị egwu ma na-emetụta steeti nke mkpụrụ ndụ beta.

Ihe ngbanwe

Ndepụta nke contraindications maka iji NovoNorm na ọrịa shuga mellitus:

Nhọrọ onunu ogwu

NovoNorm na-a drinkụ 15 nkeji tupu iri nri carbohydrate. Ntụziaka ahụ na-atụ aro ikesa ya n'ime usoro onunu ogwu iri abụọ na anọ kwa ụbọchị n'otu akụkụ.

Usoro ọgwụgwọ usoro onunu ogwu bu ihe nlere nke glycemia. Iwu Nhọrọ:

1. Otu usoro amalite bụ 0,5 mg.
2. Ọ bụrụ na enweghị ụgwọ maka ọrịa shuga, ọ na-abawanye mgbe izu 1 gachara 1 mg.
3. Site n’iwelite ọ̀ganị site na 0,5 mg, enwere ike ibute ya ruo 4 mg na 1 dose. Usoro kachasị elu kwa ụbọchị bụ 16 mg. Ọ bụrụ na o nyeghị nchịkwa ọrịa shuga, onye ọrịa ahụ kwesịrị ịgbanwe nhazi ahụ, ma ọ bụrụ na usoro a adịghị arụ ọrụ, gbanwee gaa ọgwụ siri ike ma ọ bụ insulin.

Omume achọghị omume

Dabere na nyocha nke ndị ọrịa mamịrị na-a theụ ọgwụ ahụ, ọtụtụ mgbe ha na-enweta ọdịda shuga na-adịghị mma mgbe ha takingụsịrị ọgwụ ahụ. Ihe kpatara ya nwere ike bụrụ oke ọgwụ repaglinide, enweghị carbohydrates na nri, mgbaze nke onwe ya, nrụgide anụ ahụ na nke uche. Ntuziaka ahụ na-enyocha ihe ize ndụ nke hypoglycemia site na ugboro ugboro (1-10%). Site na otu ihe ga - ekwe omume - afọ ọsịsa na mgbu nke mpaghara apịtị.

Nsonaazụ ndị ọzọ dịkarị obere, na erughị 0.1% nke ndị ọrịa. NovoNorm nwere ike ibute ihe nfụkasị, afọ ntachi, ọgbụgbọ, na-enye aka na ụba mmepụta nke enzymes imeju.

Analogs na dochie NovoNorma

Kedu ihe nwere ike dochie NovoNorm ma ọ bụrụ na ọ bụ enweghị nkwekọrịta ma ọ bụ na ọ nweghị n'ụlọ ahịa ọgwụ:

Na mellitus na-arịa ọrịa shuga, nnọchi NovoNorm na analogues zuru oke nwere ike ịme onwe ha, ha na-a drugụ ọgwụ ọhụrụ na otu oke. Chinggbanwe na mbadamba ihe ọ bụla ọzọ sitere na tebụl dị n'elu chọrọ ọgwụ ịhọrọ ya naanị enwere ike ịme ya n'okpuru nlekọta na ndenye dọkịta.

Nyocha banyere ọgwụ